Statistics

Total Visits

Views
Low-dose metronomic oral cyclophosphamide plus prednisone for metastatic castration resistant prostate cancer (mCRPC) patients36

Select a period of time:

Number of views in the range

Views
Low-dose metronomic oral cyclophosphamide plus prednisone for metastatic castration resistant prostate cancer (mCRPC) patients24

Views

Views
December 20242
January 20253
February 20250
March 202517
April 20252
May 20250
June 20250
Download CSV file
 untranslated
 untranslated

Top country views

Views
Singapore17
United States3
United Kingdom2
Canada1
Spain1
 

Top cities views

Views
Houston2
Council Bluffs1
Toronto1